Endo Pharm. Inc. v. Fed. Trade Comm'n
345 F. Supp. 3d 554
E.D. Pa.2018Background
- FTC originally filed a Section 13(b) enforcement suit in E.D. Pa. against Endo, Watson (Allergan entities), Impax and others alleging reverse-payment agreements (Lidoderm, Opana). Defendants moved to dismiss, arguing Section 13(b) does not permit suit limited to past conduct.
- The Court severed Lidoderm and Opana claims but refused to transfer; FTC voluntarily dismissed the case and later refiled the Lidoderm enforcement action in N.D. Cal. Plaintiff manufacturers (Watson, Allergan) then filed declaratory judgment suits in E.D. Pa. seeking a ruling that Section 13(b) cannot be used to challenge past conduct or to obtain disgorgement/restitution.
- FTC moved to dismiss the declaratory judgment actions, arguing plaintiffs have adequate remedies in the California enforcement action and no final agency action exists for APA review; the Court stayed the California action pending resolution here.
- The Court found plaintiffs failed to state an APA claim because the FTC’s filing is not a final agency action and plaintiffs have an adequate remedy by defending the California suit.
- The Court also declined to exercise jurisdiction under the Declaratory Judgment Act (DJA) as the extra‑enforcement challenge was unripe and discretionary factors (including Reifer factors and concerns about duplicative litigation and deference to the Government’s coercive suit) counseled dismissal.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether plaintiffs may obtain APA review of the FTC's filing as final agency action | FTC's decision to sue is final and causes legal effects; APA review is proper | Filing an enforcement suit is not "final agency action" and defendants have an adequate remedy in court | APA claim dismissed: filing is not final agency action and plaintiffs have adequate remedy in the enforcement suit |
| Whether DJA jurisdiction is available to obtain extra‑enforcement review | DJA permits declaratory relief because an actual controversy exists and MedImmune allows pre‑enforcement challenges | DJA should not be used to circumvent Congress's review scheme; plaintiffs can raise defenses in the enforcement action | Court has DJA jurisdiction in the sense of standing, but declines to exercise it (discretionary dismissal) |
| Ripeness of the extra‑enforcement declaratory claim | Issue is purely legal and ripe for judicial decision; defendants will suffer hardship if forced to litigate in separate forum | No immediate hardship comparable to Abbott Labs; absence of final agency action and adequate remedy in enforcement suit make the claim unripe | Claim unripe under Abbott Labs: fitness and hardship tests not met, so DJA relief denied |
| Whether court should nonetheless exercise DJA jurisdiction (Reifer factors) | Plaintiffs argue judicial efficiency and prior briefing favor deciding the issue here | FTC emphasizes deference to venue choice, avoidance of duplicative litigation, and priority to coercive suits | Most Reifer factors (fitness to resolve controversy, availability of other remedies, avoidance of duplicative litigation, public interest) weigh against exercising jurisdiction; court declines jurisdiction |
Key Cases Cited
- United States Army Corps of Eng'rs v. Hawkes Co., 136 S. Ct. 1807 (2016) (framework for determining final agency action)
- Bennett v. Spear, 520 U.S. 154 (1997) (Bennett two‑prong finality test)
- Abbott Laboratories v. Gardner, 387 U.S. 136 (1967) (ripeness test: fitness and hardship for pre‑enforcement review)
- MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007) (government threats can justify declaratory relief without first incurring liability)
- F.T.C. v. Standard Oil Co. of California, 449 U.S. 232 (1980) (limits on pre‑adjudication review of FTC administrative complaints)
- Moog Indus. v. Fed. Trade Comm'n, 355 U.S. 411 (1958) (deference to FTC enforcement policy and venue choices)
- Shea v. Office of Thrift Supervision, 934 F.2d 41 (3d Cir. 1991) (effects‑driven approach to finality)
- Reifer v. Westport Ins. Corp., 751 F.3d 129 (3d Cir. 2014) (factors guiding district court discretion to hear DJA actions)